On July 8, Ping An Good Doctor (01833.HK) rose 5.26% in regular trading, trading at HK$7.59/share, with turnover of approximately HK$75.66 million.

On the news front, the company announced on July 7 a deep strategic cooperation with Pfizer China. Leveraging Ping An's medical and health services, commercial insurance payment capabilities, enterprise health management, AI medical technology, and its user base of over 100 million, combined with Pfizer's strengths in innovative drug R&D and evidence-based medicine, the two parties will jointly build a dual closed-loop system encompassing a commercial closed-loop for medical-pharmaceutical-insurance integration and a full disease-course management closed-loop. CEO He Mingke stated that deep integration of medicine, pharmaceuticals, and insurance represents a core development direction for internet healthcare.

On fundamentals, the company reported Q1 revenue of RMB 1.159 billion, up 9.1% year-over-year, with adjusted net profit of RMB 84.4 million, up 45.8%. CICC initiated coverage with an Outperform rating and a target price of HK$14.20.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)